Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis was written by Rampotas, Alexandros;Wilson, Matthew R.;Lomas, Oliver;Denny, Nicholas;Leary, Heather;Ferguson, Graeme;McKay, Pamela;Ebsworth, Tim;Miller, Jonathan;Shah, Nimish;Martinez-Calle, Nicolas;Bishton, Mark;Everden, Angharad;Tucker, David;El-Hassad, Ezzat;Hennessy, Brian;Doherty, Dearbhla;Prideaux, Steve;Faryal, Rehman;Hayat, Amjad;Keohane, Clodagh;Marr, Helen;Gibb, Adam;Pocock, Rachael;Lambert, Jonathan;Lacey, Rachel;Elmusharaf, Nagah;Clifford, Ruth;Eyre, Toby A.. And the article was included in British Journal of Haematology in 2021.SDS of cas: 16506-27-7 The following contents are mentioned in the article:
Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clin. challenge. Front-line attenuated or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenuated immunochemotherapy in 95 patients with MCL across 19 centers in the UK and Ireland considered unfit for full-dose rituximab-bendamustine or rituximab-cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP). Regimens examined were rituximab-cyclophosphamide, vincristine, prednisolone (R-CVP) (n = 19), dose-attenuated R-CHOP (n = 22), dose attenuated rituximab-bendamustine (n = 24) and rituximab-chlorambucil (n = 30). The primary outcome was progression-free survival (PFS). The secondary outcomes included overall response, overall survival (OS) and toxicity. The median (range) age was 79 (58-89) years and 50% were aged ≥80 years. The median (range) Cumulative Illness Rating Scale-Geriatric score was 6 (0-24). The median PFS for all patients was 15 mo 95% confidence interval (CI) (8·7-21·2) and median OS was 31·4 mo (95% CI 19·7-43·2). By multivariable anal. (MVA), the only clin. factor associated with an inferior PFS was blastoid morphol. hazard ratio (HR) 2·90, P = 0·01. Notably, higher treatment intensity (R-CHOP/R-bendamustine composite) provided an independently superior PFS compared with R-CVP/R-chlorambucil (MVA HR 0·49, P = 0·02). Factors associated with inferior OS by MVA were Eastern Cooperative Oncol. Group Performance Status (HR 2·14, P = 0·04), blastoid morphol. (HR 4·08, P = 0·001) and progression of disease at <24 mo status (HR 5·68, P < 0·001). Overall, survival after front-line dose-attenuated immunochemotherapy is unsatisfactory. Clin. trials investigating novel agents such as Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors in this specific clin. setting are warranted. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).SDS of cas: 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem